Results 21 to 30 of about 8,708 (251)

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Adedoyin, Adedayo, Caro, Luzelena, De Waele, Jan, Gadzicki, Elaine, Kuti, Joseph L, Larson, Kajal B, Nicolau, David P, Rhee, Elizabeth G, Yu, Brian, Zeng, Zhen   +9 more
core   +1 more source

Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Critical Care, 2022
Background Ceftolozane/tazobactam, a combination antibacterial agent comprising an anti-pseudomonal cephalosporin and β-lactamase inhibitor, is approved for the treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in ...
Marin H. Kollef, Jean-François Timsit, Ignacio Martin-Loeches, Richard G. Wunderink, Jennifer A. Huntington, Erin H. Jensen, Brian Yu, Christopher J. Bruno   +7 more
doaj   +1 more source

European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria [PDF]

, 2020
Background Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate ...
De Waele, Jan, Friggeri, Arnaud, Garnacho-Montero, José, Gustin, Marie Paule, Jean, Astrid, Kohlenberg, Anke, Lepape, Alain, Monnet, Dominique L., Savey, Anne, Vanhems, Philippe   +9 more
core   +2 more sources

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study

Journal of Translational Medicine, 2020
Background Extracorporeal membrane oxygenation (ECMO) is increasingly used in intensive care units and can modify drug pharmacokinetics and lead to under-exposure associated with treatment failure. Ceftolozane/tazobactam is an antibiotic combination used
Camille Mané, Clément Delmas, Jean Porterie, Géraldine Jourdan, Patrick Verwaerde, Bertrand Marcheix, Didier Concordet, Bernard Georges, Stéphanie Ruiz, Peggy Gandia   +9 more
doaj   +1 more source

Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates

Medicina, 2023
Background: Gram-negative rods are one of the most commonly isolated bacteria within human infections. These microorganisms are typically opportunistic pathogens that pose a serious threat to public health due to the possibility of transmission in the ...
Alicja Sękowska, Marta Grabowska, Tomasz Bogiel   +2 more
doaj   +1 more source

Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR <i>Pseudomonas</i> <i>aeruginosa</i> (PUMA). [PDF]

Antimicrob Agents Chemother
Ceftolozane/tazobactam and polymyxin-based regimens are frequently used to treat pneumonia caused by multi-drug-resistant P. aeruginosa (MDR-PSA). However, comparative data on global clinical outcomes between these therapies are limited. A multi-centered
Lodise TP, Min J, Nathanson BH, Yücel E.   +3 more
europepmc   +2 more sources

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study

Brazilian Journal of Infectious Diseases, 2020
Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens.
Felipe Francisco Tuon, Juliette Cieslinski, Suellen da Silva Rodrigues, Fernando Brandão Serra, Marina Della-Negra de Paula   +4 more
doaj   +1 more source

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study

New Microbes and New Infections, 2021
Ceftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms.
J. Belkhair, S. Nachat, S. Rouhi, H. Ouassif, S. Abbassi, N. Soraa   +5 more
doaj   +1 more source

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia [PDF]

, 2020
BACKGROUND: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB). OBJECTIVES: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical ...
Conejo, Mª del Carmen, Delgado Valverde, María Mercedes, Fernández Cuenca, Felipe Manuel, Pascual Hernández, Álvaro, Serrano, Lara   +4 more
core   +1 more source

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A, A, A, A, A, A, A, A, A, A, A, A, A, AA, AC, AH, AJ, AK, AK, AM, AW, B, B, B, B, BJ, C, C, C, C, CA, CA, CE, D, D, D, DG, DP, E, EA, EE, F, F, F, F, FA, FM, FM, G, G, G, G, G, G, G, GA, GP, H, H, H, H, HAS, HE, I, I, I, I, IJ, J, J, JA, JE, JF, JG, JJ, JJ, JL, JR, JR, JR, JV, K, K, K, K, KA, KC, KYY, L, LJ, M, M, M, M, M, M, M, M, M, M, M, M, M, MA, MA, MA, MA, MC, MG, MM, MN, MP, N, N, NT, O, OR, P, P, P, P, PF, PK, R, R, R, R, R, R, R, RB, RG, RM, RR, RR, RS, RV, S, S, S, S, S, S, S, S, S, Sartelli, SJ, SK, SK, SM, SR, SR, SY, T, T, TL, TM, V, V, VG, VN, W, W, W, WL, WR, Y, YF, YH, YR, YS, Z, ZJ   +173 more
core   +16 more sources